Literature DB >> 20399313

Management of hepatitis C virus-related mixed cryoglobulinemia.

Francesco Iannuzzella1, Augusto Vaglio, Giovanni Garini.   

Abstract

Mixed cryoglobulinemia is a chronic immune complex-mediated disease strongly associated with hepatitis C virus (HCV) infection. Mixed cryoglobulinemia is a vasculitis of small and medium-sized arteries and veins, due to the deposition of complexes of antigen, cryoglobulin and complement in the vessel walls. The main clinical features of mixed cryoglobulinemia vasculitis include the triad of palpable purpura, arthralgias, and weakness, and other pathological conditions such as glomerulonephritis, peripheral neuropathy, skin ulcers, and widespread vasculitis. The treatment of HCV-related mixed cryoglobulinemia is difficult due to the multifactorial origin and clinical polymorphism of the syndrome. It can be directed to eradicate the HCV infection, suppress the B-cell clonal expansion and cryoglobulin production, or ameliorate symptoms. The choice of the most appropriate treatment is strictly related to the assessment of disease activity, and to the extent and severity of organ involvement. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20399313     DOI: 10.1016/j.amjmed.2009.09.038

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  15 in total

Review 1.  Principles of separation: indications and therapeutic targets for plasma exchange.

Authors:  Mark E Williams; Rasheed A Balogun
Journal:  Clin J Am Soc Nephrol       Date:  2013-10-31       Impact factor: 8.237

2.  Extrahepatic manifestations of hepatitis C virus (HCV).

Authors:  David G Samuel; Ian W Rees
Journal:  Frontline Gastroenterol       Date:  2013-05-24

3.  Hepatitis C virus and its renal manifestations: a review and update.

Authors:  Nyan Latt; Nada Alachkar; Ahmet Gurakar
Journal:  Gastroenterol Hepatol (N Y)       Date:  2012-07

4.  Differential regulation of interleukin-12 (IL-12)/IL-23 by Tim-3 drives T(H)17 cell development during hepatitis C virus infection.

Authors:  Jia M Wang; Lei Shi; Cheng J Ma; Xiao J Ji; Ruo S Ying; Xiao Y Wu; Ke S Wang; Guangyu Li; Jonathan P Moorman; Zhi Q Yao
Journal:  J Virol       Date:  2013-02-06       Impact factor: 5.103

Review 5.  Hepatitis C virus associated glomerulopathies.

Authors:  Abdullah Ozkok; Alaattin Yildiz
Journal:  World J Gastroenterol       Date:  2014-06-28       Impact factor: 5.742

Review 6.  Advances in HCV and Cryoglobulinemic Vasculitis in the Era of DAAs: Are We at the End of the Road?

Authors:  Chalermrat Bunchorntavakul; Robert Mitrani; K Rajender Reddy
Journal:  J Clin Exp Hepatol       Date:  2017-12-07

7.  An interesting rash: leucocytoclastic vasculitis with type 2 cryoglobulinaemia.

Authors:  Gurdeep Singh Mannu
Journal:  JRSM Short Rep       Date:  2010-11-22

8.  Peripheral ulcerative keratitis and necrotizing scleritis initiated by trauma in the setting of mixed cryoglobulinemia.

Authors:  Cameron Campbell Johnson; Derek Hunter Ohlstein
Journal:  Case Rep Ophthalmol       Date:  2011-12-12

Review 9.  Membranoproliferative glomerulonephritis, type II cryoglobulinemia and triple therapy for hepatitis C: a case series and review of the literature.

Authors:  Kevin Humphries; Jama M Darling; A Sidney Barritt
Journal:  Dig Dis Sci       Date:  2014-03-16       Impact factor: 3.487

Review 10.  Extrahepatic manifestations and autoantibodies in patients with hepatitis C virus infection.

Authors:  Takashi Himoto; Tsutomu Masaki
Journal:  Clin Dev Immunol       Date:  2012-09-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.